P2RX7 and myeloid sarcoma: After disease onset, administration of oxATP reduced clinical outcomes and demyelination extent (Matute et al., 2007), likely acting on astroglial and microglial P2X7, supporting the hypothesis that P2X7 receptor blockers could have a role in preventing/improving MS symptoms.